Larvol Delta - Artiva-Announces-Positive-Initial-Clinical-Data-with-AlloNK-Across-Multiple-Autoimmune-Diseases-and-FDA-Alignment-to-Initiate-Phase-3-Registrational-Trial-in-Rheumatoid-Arthritis-in-2026

AlloNK (GCC4001) - Artiva Biotherapeutics

https://www.globenewswire.com/news-release/2026/05/08/3290957/0/en/artiva-announces-positive-initial-clinical-data-with-allonk-across-multiple-autoimmune-diseases-and-fda-alignment-to-initiate-phase-3-registrational-trial-in-rheumatoid-arthritis-i.html

May 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next